October 2018, PARIS – Keen Eye, a French technology company specialized in image analysis for the life science industry, announced today a strategic partnership agreement with Iris Pharma, a world-wide leading ophthalmology-focused contract research organization (CRO) that offers preclinical and clinical drug / device development services. The partnership aims at providing Iris Pharma artificial intelligence (AI) applications to make assays faster, more reliable and more efficient.
For Sylvain Berlemont, Founder & CEO of Keen Eye, « We are very happy to team up and bring our expertise in computer vision to Iris Pharma. Through this partnership, we are expecting to contribute to the most challenging image-based assays to better fight eye diseases.»
For Yann Quentric, President of Iris Pharma, « The advanced AI technology of Keen Eye allows us to optimize the performance of the bioimaging analysis during the preclinical ophthalmic drug development, and in the future for clinical development. Their solution is faster than classical methods, robust and reliable, erasing inter-individual variability, improving Iris Pharma and its customers ability to develop ocular innovative products.»
About Keen Eye
Seeing Beyond Pixels
Founded in 2013, Keen Eye is a technology company based in Paris; aiming at bringing AI into every laboratory for the benefit of biologists, pathologists and patients. The company is building decision-support and GLP-compliant image analysis solutions to accelerate the development of new therapies with better, faster and accurate analytics.
Keen Eye develops web-based solutions which help biologists and pathologists that usually spend thousands of hours on the microscope. Among others, Keen Eye delivers image quantification applications using its deep learning technology.
For more information: www.keeneye.ai
About Iris Pharma
A leading CRO dedicated to ophthalmology, Iris Pharma helps clients around the world navigate every stage of the drug and device development process – including in vivo screening, proof of concept, ocular efficacy, GLP preclinical studies, bioanalysis, clinical trials, and marketing surveys. This CRO has expertise in all ophthalmic indications, and supports clients ranging from small start-ups to large pharmaceutical companies in moving forward products that directly or indirectly affect eye health.
For more information: www.iris-pharma.com